Your session is about to expire
← Back to Search
Ointment
AZR-MD-001 Low Dose for Meibomian Gland Dysfunction
Phase 2
Waitlist Available
Led By Stephanie L Watson
Research Sponsored by Azura Ophthalmics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up value at month 3 minus value at baseline
Awards & highlights
Study Summary
This trial is testing a new ointment for people with Meibomian Gland Dysfunction and evaporative Dry Eye Disease.
Eligible Conditions
- Meibomian Gland Dysfunction
- Dry Eye Syndrome
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ value at month 3 minus value at baseline
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~value at month 3 minus value at baseline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Meibomian Glands Yielding Liquid Secretion (MGYLS)
Ocular Surface Disease Index (OSDI) Total Score
Secondary outcome measures
Meibum Gland Secretion Score (MGS)
Side effects data
From 2022 Phase 2 trial • 321 Patients • NCT0365205113%
Foreign body sensation
13%
Administration site reaction
6%
Application site pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Stage 1: AZR-MD-001 Vehicle
Stage 2: AZR-MD-001 Mid Dose
Stage 2: AZR-MD-001 Vehicle
Stage 2: AZR-MD-001 High Dose
Stage 1: AZR-MD-001 Low Dose
Stage 1: AZR-MD-001 Mid Dose
Stage 1: AZR-MD-001 High Dose
Trial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: AZR-MD-001 Mid DoseExperimental Treatment1 Intervention
AZR-MD-001 Mid Dose will be dosed up to once daily.
Group II: AZR-MD-001 Low DoseExperimental Treatment1 Intervention
AZR-MD-001 Low Dose will be dosed up to once daily.
Group III: AZR-MD-001 High DoseExperimental Treatment1 Intervention
AZR-MD-001 High Dose will be dosed up to once daily.
Group IV: AZR-MD-001 VehiclePlacebo Group1 Intervention
AZR-MD-001 Vehicle will be dosed up to once daily.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AZR-MD-001 Low Dose
2018
Completed Phase 2
~330
AZR-MD-001 Mid Dose
2018
Completed Phase 2
~330
AZR-MD-001 High Dose
2018
Completed Phase 2
~330
Find a Location
Who is running the clinical trial?
Cliantha ResearchUNKNOWN
Azura OphthalmicsLead Sponsor
5 Previous Clinical Trials
656 Total Patients Enrolled
3 Trials studying Meibomian Gland Dysfunction
89 Patients Enrolled for Meibomian Gland Dysfunction
Syneos HealthOTHER
172 Previous Clinical Trials
68,133 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Who else is applying?
What state do they live in?
New York
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Share this study with friends
Copy Link
Messenger